New Industrials Imperatives

L.E.K.’s John Goddard and Carol Wingard discuss findings from a new special report: “New Imperatives: Why Global Industrials Must Shift Strategic Priorities” where CEOs of major global industrial firms discuss how they’ll respond to critical challenges rooted in slow growth, disruptive technologies, unforeseen competitive threats and the impact of the Industrial Internet of Things. Watch now to learn more about why global industrials must shift strategic priorities or potentially get left behind.

Watch Video »

Special Report

Global pharma companies face growing uncertainty over changes to Japan’s drug pricing system. The market is moving away from a system that has historically provided relatively favorable pricing and access to one that is likely to be more value-oriented and restrictive. New special report summarizes the issues, proposes possible future states and highlights imperatives for the pharmaceutical industry to adapt to the changing reality of the Japanese market.

View Report »

Thought Leadership

In this Executive Insights, L.E.K. London Partner Peter Ward discusses why, nearly one year after Brexit , UK based international financial services firms are planning for the worst but still hoping for the best. Brexit has wounded the City of London, but negotiations have a long way to run and the smart money will keep its options as open as possible.

One common theme that we hear as we speak to executives industrial companies is the enormous challenge they face in achieving growth. This Executive Insights examines how industrial companies can employ an Edge Strategy® mindset to create incremental profits by presenting customers with additional offers that surround the core product or service that defines their business.

Virtual reality and augmented reality will transform retailing. But how, exactly? L.E.K. Consulting recently surveyed 1,000 consumers who had already experienced AR and VR technology. The results offer an initial look at what consumers hope to do when they shop in augmented or virtual realities.

As the number of OTT offerings continues to climb, the opportunity to consolidate the management of these services on behalf of consumers is likely to accelerate as well. As the number of OTT offerings continues to climb, the opportunity to consolidate the management of these services on behalf of consumers is likely to accelerate as well. This Executive Insights discusses key factors that are likely to support OTT aggregation.

In this Executive Insights, L.E.K. Consulting explores how the use of technology to increase efficiency and enhance quality is transforming the pharma sector. The challenge will be to determine the most effective route to offer truly differentiated services.

In this Executive Insights, L.E.K. Consulting examines how homecare providers can address pressure to reduce healthcare costs while maintaining profitability by consolidating local market share in their core segments and improving operational efficiencies.

Small and mid-sized medtech companies face some unique challenges in the marketplace, but there are a number of strategies that will help level the playing field and even allow smaller players to thrive. It has rarely been tougher to be a small or midsize medtech in the U.S. market. Leaders in smaller medtech organizations face numerous challenges. This Executive Insights takes a look at strategies for smaller players in a market that is becoming increasingly challenging.

Companion diagnostics (CDx) are key to delivering personalized medicine in oncology. However, commercializing CDx products remains a challenge for pharmaceutical companies as it may require touching unfamiliar stakeholders and processes as well as performing a range of incremental activities.

Economic recovery, regulatory updates and the need to upgrade Brazil’s existing terminals are turning port terminals into attractive opportunities for investors. This Executive Insights examines why the timing is right for port infrastructure investment in Brazil.

In the late 2000s, the Brazilian Development Bank established Profarma, a program with a line of credit intended to create a Brazilian national super-pharma company. But Profarma did not deliver. This Executive Insights will examine how economic recovery, new regulations and competition will drive the future of Brazil’s pharmaceutical market.

a
a
a
a
a
a
a
a
a
a